Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

173 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Pegcetacoplan for the treatment of geographic atrophy secondary to age-related macular degeneration (OAKS and DERBY): two multicentre, randomised, double-masked, sham-controlled, phase 3 trials.
Heier JS, Lad EM, Holz FG, Rosenfeld PJ, Guymer RH, Boyer D, Grossi F, Baumal CR, Korobelnik JF, Slakter JS, Waheed NK, Metlapally R, Pearce I, Steinle N, Francone AA, Hu A, Lally DR, Deschatelets P, Francois C, Bliss C, Staurenghi G, Monés J, Singh RP, Ribeiro R, Wykoff CC; OAKS and DERBY study investigators. Heier JS, et al. Among authors: bliss c. Lancet. 2023 Oct 21;402(10411):1434-1448. doi: 10.1016/S0140-6736(23)01520-9. Lancet. 2023. PMID: 37865470 Clinical Trial.
Correspondence.
Baumal C, Bliss C, Jones D, Ribeiro R. Baumal C, et al. Among authors: bliss c. Retina. 2024 Jan 1;44(1):e6-e9. doi: 10.1097/IAE.0000000000003903. Retina. 2024. PMID: 37536663 No abstract available.
Pegcetacoplan for the treatment of geographic atrophy due to age-related macular degeneration: a plain language summary of OAKS and DERBY clinical studies.
Heier JS, Lad EM, Holz FG, Rosenfeld PJ, Guymer RH, Boyer D, Grossi F, Baumal CR, Korobelnik JF, Slakter JS, Waheed NK, Metlapally R, Pearce I, Steinle N, Francone AA, Hu A, Lally DR, Deschatelets P, Francois C, Bliss C, Staurenghi G, Monés J, Singh RP, Ribeiro R, Wykoff CC. Heier JS, et al. Among authors: bliss c. Immunotherapy. 2025 Jan 17:1-15. doi: 10.1080/1750743X.2025.2449760. Online ahead of print. Immunotherapy. 2025. PMID: 39819346 Free article.
Carotid Artery Stenting.
Li J, Feldman DN, Klein AJ, Malas MB, Metzger DC, Parikh SA, Roubin GS, Soukas PA, Tsai S, Gray WA; Members of the SCAI 2024 Think Tank Peripheral Consortium; Bliss C, Brounstein K, Canorea-Vega F, Dean R, Donnelly G, Farrel L, Gleason S, Hughes C, Kohler M, McGonigle J, Minor DJ, Newell A, O'Hara J, Perez O, Rangwala N, Sachar R, Williams J. Li J, et al. Among authors: bliss c. J Soc Cardiovasc Angiogr Interv. 2024 Dec 19;3(12):102435. doi: 10.1016/j.jscai.2024.102435. eCollection 2024 Dec. J Soc Cardiovasc Angiogr Interv. 2024. PMID: 39807228 Free PMC article. No abstract available.
Evaluation of a novel malaria anti-sporozoite vaccine candidate, R21 in Matrix-M adjuvant, in the UK and Burkina Faso: two phase 1, first-in-human trials.
Venkatraman N, Tiono AB, Bowyer G, Bellamy DG, Stockdale LK, Powlson J, Collins KA, Coulibaly S, Datoo MS, Silman D, Ouedraogo A, Nébié I, Imoukhuede EB, Brod F, Folegatti P, Dickinson-Craig E, Jamieson S, Bougouma EC, Wright D, Diarra A, Bliss CM, Morter R, Glenn G, Fries LF, Reimer JM, Lövgren-Bengtsson K, Baker M, Poulton I, Moyle S, Berrie E, Green N, Mukhopadhyay E, Viebig NK, Angus B, Lawrie A, Roberts R, Gilbert SC, Lewis DJM, Sirima SB, Ewer KJ, Hill AVS. Venkatraman N, et al. Among authors: bliss cm. Lancet Microbe. 2024 Dec 17:100868. doi: 10.1016/S2666-5247(24)00084-3. Online ahead of print. Lancet Microbe. 2024. PMID: 39805302 Free article.
Predictive Validity of the Academy of Nutrition and Dietetics/American Society for Parental Nutrition Indicators to Diagnose Malnutrition and the Screening Tool for Risk on Nutritional Status and Growth among Hospitalized Children Relative to Medical Outcomes.
Jimenez EY, Lamers-Johnson E, Long JM, Woodcock L, Bliss C, Steiber AL. Jimenez EY, et al. Among authors: bliss c. J Pediatr. 2025 Jan;276:114288. doi: 10.1016/j.jpeds.2024.114288. Epub 2024 Sep 2. J Pediatr. 2025. PMID: 39233117 Free article.
A pseudotyped adenovirus serotype 5 vector with serotype 49 fiber knob is an effective vector for vaccine and gene therapy applications.
Bliss CM, Hulin-Curtis SL, Williams M, Marušková M, Davies JA, Statkute E, Baker AT, Stack L, Kerstetter L, Kerr-Jones LE, Milward KF, Russell G, George SJ, Badder LM, Stanton RJ, Coughlan L, Humphreys IR, Parker AL. Bliss CM, et al. Mol Ther Methods Clin Dev. 2024 Jul 30;32(3):101308. doi: 10.1016/j.omtm.2024.101308. eCollection 2024 Sep 12. Mol Ther Methods Clin Dev. 2024. PMID: 39206304 Free PMC article.
A chimeric haemagglutinin-based universal influenza virus vaccine boosts human cellular immune responses directed towards the conserved haemagglutinin stalk domain and the viral nucleoprotein.
Bliss CM, Nachbagauer R, Mariottini C, Cuevas F, Feser J, Naficy A, Bernstein DI, Guptill J, Walter EB, Berlanda-Scorza F, Innis BL, García-Sastre A, Palese P, Krammer F, Coughlan L. Bliss CM, et al. EBioMedicine. 2024 Jun;104:105153. doi: 10.1016/j.ebiom.2024.105153. Epub 2024 May 27. EBioMedicine. 2024. PMID: 38805853 Free PMC article. Clinical Trial.
173 results